Federal Register / Vol. 72, No. 38 / Tuesday, February 27, 2007 / Notices 8791 

(1) Pursuant to subsection (b) of 

section 337 of the Tariff Act of 1930, as 

amended, an investigation be instituted 

to determine whether there is a 

violation of subsection (a)(1)(B) of 

section 337 in the importation into the 

United States, the sale for importation, 

or the sale within the United States after 

importation of certain lighting products, 

components thereof, and products 

containing the same by reason of 

infringement of one or more of claims 

23, 26, and 27 of U.S. Patent No. 

6,082,878, and claims 1 and 7 of U.S. 

Patent No. 5,662,413, and whether an 

industry in the United States exists as 

required by subsection (a)(2) of section 

337; 

(2) For the purpose of the 

investigation so instituted, the following 

are hereby named as parties upon which 

this notice of investigation shall be 

served: 

(a) The complainant is—Cooper 

Lighting, Inc., 1121 Highway 74 South, 

Peachtree City, GA 30269. 

(b) The respondents are the following 

entities alleged to be in violation of 

section 337, and are the parties upon 

which the complaint is to be served: 

Cordelia Lighting, Inc., 20101 South 

Santa Fe Avenue, Rancho Dominguez, 

CA 90221. 

Jimway, Inc., 20101 South Santa Fe 

Avenue, Rancho Dominguez, CA 

90221. 

(c) The Commission investigative 

attorney, party to this investigation, is 

Bryan F. Moore, Esq., Office of Unfair 

Import Investigations, U.S. International 

Trade Commission, 500 E Street, SW., 

Room 401–I, Washington, DC 20436; 

and 

(3) For the investigation so instituted, 

the Honorable Charles E. Bullock is 

designated as the presiding 

administrative law judge. 

Responses to the complaint and the 

notice of investigation must be 

submitted by the named respondents in 

accordance with section 210.13 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.13. Pursuant to 

19 CFR 201.16(d) and 210.13(a), such 

responses will be considered by the 

Commission if received not later than 20 

days after the date of service by the 

Commission of the complaint and the 

notice of investigation. Extensions of 

time for submitting responses to the 

complaint and the notice of 

investigation will not be granted unless 

good cause therefor is shown. 

Failure of a respondent to file a timely 

response to each allegation in the 

complaint and in this notice may be 

deemed to constitute a waiver of the 

right to appear and contest the 

allegations of the complaint and this 

notice, and to authorize the 

administrative law judge and the 

Commission, without further notice to 

the respondent, to find the facts to be as 

alleged in the complaint and this notice 

and to enter an initial determination 

and a final determination containing 

such findings, and may result in the 

issuance of a limited exclusion order or 

cease and desist order or both directed 

against the respondent. 

Issued: February 21, 2007. 

By order of the Commission. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. E7–3364 Filed 2–26–07; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–550] 

In the Matter of Certain Modified 

Vaccinia Ankara (‘‘MVA’’) Viruses and 

Vaccines and Pharmaceutical 

Compositions Based Thereon; Notice 

of Commission Decision to Remand 

the Final Initial Determination Finding 

No Violation of Section 337 and To 

Extend the Target Date for Completion 

of the Investigation 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission has determined to remand 

the final initial determination (‘‘final 

ID’’) of the presiding administrative law 

judge (‘‘ALJ’’) finding no violation of 

section 337 of the Tariff Act of 1930, as 

amended, 19 U.S.C. 1337 (‘‘section 

337’’), in the above-captioned 

investigation and to extend the target 

date for completion of the investigation 

to October 19, 2007. 

FOR FURTHER INFORMATION CONTACT: 

James A. Worth, Office of the General 

Counsel, U.S. International Trade 

Commission, 500 E Street, SW., 

Washington, DC 20436, telephone (202) 

205–3065. Copies of non-confidential 

documents filed in connection with this 

investigation are or will be available for 

inspection during official business 

hours (8:45 a.m. to 5:15 p.m.) in the 

Office of the Secretary, U.S. 

International Trade Commission, 500 E 

Street, SW., Washington, DC 20436, 

telephone (202) 205–2000. General 

information concerning the Commission 

may also be obtained by accessing its 

Internet server (http://www.usitc.gov). 

The public record for this investigation 

may be viewed on the Commission’s 

electronic docket (EDIS) at http:// 

edis.usitc.gov. Hearing-impaired 

persons are advised that information on 

this matter can be obtained by 

contacting the Commission’s TDD 

terminal on (202) 205–1810. 

SUPPLEMENTARY INFORMATION: This 

investigation was instituted on 

September 23, 2005, based on a 

complaint filed by Bavarian Nordic 

A/S of Denmark (‘‘Bavarian Nordic’’). 

The complaint alleged violations of 

section 337 in the importation into the 

United States, the sale for importation, 

and the sale within the United States 

after importation of certain Modified 

Vaccinia Ankara (‘‘MVA’’) viruses and 

vaccines and pharmaceutical 

compositions based thereon by reason of 

infringement of various claims of United 

States Patent Nos. 6,761,893 and 

6,913,752. The complaint also alleged 

violations of section 337 in the 

importation of certain MVA viruses and 

vaccines and pharmaceutical 

compositions based thereon or in the 

sale of such articles by reason of 

misappropriation of trade secrets, the 

threat or effect of which is to destroy or 

substantially injure an industry in the 

United States. The complaint named a 

single respondent, Acambis PLC 

(‘‘Acambis’’) of the United Kingdom. 

Only the patent allegations remain in 

this investigation. 

After a hearing and post-hearing 

briefing, the ALJ issued a final initial 

determination (‘‘final ID’’) on September 

6, 2006, finding no violation of section 

337. The ALJ held that the patents were 

infringed but invalid. 

Bavarian Nordic, Acambis, and the 

Commission investigative attorney filed 

petitions for review of the final ID. By 

notice of November 22, 2006, the 

Commission determined to review the 

final ID in its entirety, as well as Order 

No. 10, and to ask the parties for 

briefing on the issues on review and on 

remedy, public interest and bonding. 

The parties submitted their initial and 

reply briefs on December 12 and 

December 22, 2006, respectively. 

By notice of January 19, 2007, the 

Commission requested briefing on 

whether this investigation has become 

or will shortly become moot, and if so, 

whether the investigation should be 

terminated. The parties submitted 

briefing on January 26, 2007. 

The Commission has determined to 

remand the final ID to the ALJ and to 

extend the target date for completion of 

the investigation by eight months to 

October 19, 2007. 

This action is taken under the 

authority of section 337 of the Tariff Act 


cprice-sewell on PROD1PC62 with NOTICES
8792 Federal Register / Vol. 72, No. 38 / Tuesday, February 27, 2007 / Notices 

of 1930, as amended (19 U.S.C. 1337), 

and in sections 210.45(c), 210.51(a) of 

the Commission’s Rules of Practice and 

Procedure (19 CFR 210.45(c), 210.51(a)). 

By order of the Commission. 

Issued: February 21, 2007. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. E7–3390 Filed 2–26–07; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 6, 2006, and 

published in the Federal Register on 

October 18, 2006, (71 FR 61510), 

Boehringer Ingelheim Chemicals Inc., 

2820 N. Normandy Drive, Petersburg, 

Virginia 23805, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances listed in 

schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) .... I 

Amphetamine (1100) .................. II 

Methylphenidate (1724) .............. II 

Methadone (9250) ...................... II 

Methadone Intermediate (9254) II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Fentanyl(9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers for formulation 

into finished pharmaceuticals. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Boehringer Ingelheim Chemicals Inc. to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Boehringer Ingelheim 

Chemicals Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: February 16, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control Drug Enforcement, 

Administration. 

[FR Doc. E7–3296 Filed 2–26–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 21, 2006 

and published in the Federal Register 

on December 1, 2006, (71 FR 69591–

69592), Johnson Matthey, Inc., 

Pharmaceutical Materials, 2003 Nolte 

Drive, West Deptford, New Jersey 

08066–1742, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Phenylacetone (8501) .................. II 

Raw Opium (9600) ....................... II 

Concentrate of Poppy Straw 

(9670) ........................................ II 

The company plans to import the 

listed controlled substances as raw 

materials for use in the manufacture of 

bulk controlled substances for 

distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Johnson Matthey Inc to import the basic 

classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated Johnson 

Matthey Inc to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and § 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: February 16, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–3299 Filed 2–26–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 8, 2006 

and published in the Federal Register 

on November 17, 2006, (71 FR 66974), 

Kenco VPI, Division of Kenco Group 

Inc., 350 Corporate Place, Chattanooga, 

Tennessee 37419, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Nabilone (7379), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance for 

distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Kenco VPI to import the basic class of 

controlled substance is consistent with 

the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971, at this time. DEA 

has investigated Kenco VPI to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: February 16, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–3298 Filed 2–26–07; 8:45 am] 

BILLING CODE 4410–09–P 


cprice-sewell on PROD1PC62 with NOTICES